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Abstract: 
Background:  Flow-mediated dilation (FMD) of human conduit arteries is, in part, 
related to the shear stress-induced release of endothelium-derived nitric oxide (NO); 
which is an important regulator of vascular tone. However, although NO synthase 
inhibitors attenuate FMD in humans they are unable to abolish the response. Recently, 
a cytochrome P450 (CYP) epoxygenase belonging to the 2C family was linked to the 
NO- and prostacyclin-independent relaxation of conduit arteries. We therefore evaluated 
the contribution of CYP 2C9 to FMD in humans. 
Methods and results: FMD of the radial artery was determined in 12 healthy 
volunteers by high resolution ultrasound. FMD was analyzed during control conditions, 
after intra-arterial infusion (5 min) of the specific inhibitor of CYP 2C9, sulfaphenazole (4 
mg/min), L-NMMA (NO-synthase-inhibitor, 7 µmol/min) and after co-infusion of both 
compounds. Endothelium-independent vasodilation was characterized after intra-arterial 
infusion of SNP (9 µg/min, 5 min). FMD under control conditions was 11.5±0.87%, after 
sulfaphenazole 7.4±0.95% (p<0.01 vs. control), after L-NMMA 6.0±0.71% (<0.01 vs. 
control), and after co-infusion 3.9±0.73% (p<0.01 vs. control, p<0.05 vs. L-NMMA, 
p<0.01 vs. sulfaphenazole). Sulfaphenazole had no effect on endothelium-independent 
vasodilation (SNP: 19.6±1.87%, SNP + sulfaphenazole: 20.2±2.16, p=n.s.). In patients 
with chronic heart failure, the portion of FMD blocked by sulfaphenazole was not 
affected. CYP 2C was detected by immunhistochemistry in radial artery samples 
obtained from patients undergoing coronary bypass surgery. 
Conclusions: FMD in human conductance arteries is reduced after inhibition of CYP 
2C9, supporting the concept that CYP 2C metabolites contribute to the endothelium-
mediated vasodilation of peripheral conduit arteries in vivo. In patients with heart failure, 
the CYP-dependent FMD appears to be preserved. 
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Introduction 
 
Flow-mediated dilation of conductance arteries is a principle mechanism by which 
changes in flow affect vascular tone and vasodilation. Numerous experimental and, 
more recently, clinical studies have established that the shear-stress induced release of 
nitric oxide (NO) contributes to the flow-mediated vasodilation of arterial conductance 
vessels. However, we and others have noted that a residual response remains after 
blocking the production of NO and the generation of prostacyclin. 1-3 In fact, prolonged 
episodes of reactive hyperemia result in enhanced residual FMD that is not affected by 
NO synthase inhibitors.3 Experimental studies have demonstrated that additional 
endothelium-derived factors can contribute to FMD in animals. Indeed, in some arteries 
an endothelium-derived hyperpolarizing factor (EDHF) has been implicated in this 
process and it has been suggested that the residual FMD observed after the NO 
synthase blockade can be attributed to an EDHF-mediated vasorelaxation.4 
It has previously been demonstrated that a cytochrome P450 epoxygenase of the 2C 
family (CYP 2C) expressed in the endothelium plays a crucial role in the generation of 
EDHF-mediated responses in porcine coronary arteries.5 More recently, CYP 2C9 has 
been identified in the endothelium of human mammary arteries and has been shown to 
generate the vasodilator 11,12-epoxyeicosatrienoic acid (11,12-EET).6 However, in 
addition to generating EETs, the CYP 2C epoxygenase can also generate oxygen-
derived free radicals which attenuate the bioavailability of NO.6 Notably, this “EDHF 
synthase” can be efficiently and selectively inhibited by the sulfonamide sulfaphenazole 
both in animals and humans.5,7-9  
The aim of the present study was to determine whether CYP 2C9 contributes to the 
flow-induced dilation of conduit arteries in humans and whether the contribution of the 
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enzyme to FMD is attenuated or exaggerated in disease states such as chronic heart 
failure. We therefore studied the effect of sulfaphenazole on FMD of the radial artery in 
healthy volunteers and patients with chronic heart failure. 
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Methods 
 
Study population 
The study protocol was approved by the Ethics Committee of the Medizinische 
Hochschule Hannover. Twelve young healthy volunteers, who gave their informed 
consent, were included and their baseline characteristics are outlined in table 1. All 
subjects were nonsmokers, normotensive, did not take any cardiac medication, and had 
normal serum cholesterol levels. Patients with chronic heart failure (NYHA functional 
class II and III) were also included in this study. The clinical characteristics of patients 
with chronic heart failure are depicted in table 2. The functional NYHA class was 
evaluated the day before FMD-measurement. 
Measurement of FMD 
Radial artery diameters were measured using a high-resolution ultrasound system 
(ASULAB) with a precision of ± 2.5 µm. This method is well established in our 
laboratory, has an excellent reproducibility and variability, as reported previously.1,2 After 
insertion of a polyethylene catheter in the left brachial artery (nondominant arm), blood 
flow velocity was recorded continuously by an 8-MHz Doppler probe, and radial artery 
diameter was determined every 30 seconds until stable baseline values were obtained   
(30 minutes). To prevent prostaglandin production, 250 mg aspirin (Aspisol®, Bayer AG, 
Leverkusen, Germany) was given intravenously 30 minutes before measurements, a 
dose known to effectively inhibit vascular cyclooxygenase activity. Thereafter, a wrist 
arterial occlusion (8 minutes) distal of the transducer was performed and FMD in 
response to reactive hyperemic blood flow was assessed. After release of the arterial 
occlusion, arterial diameter was determined at 20 second intervals for 2 minutes then 
every 30 seconds until the diameter returned to baseline. Arterial blood pressure and 
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heart rate were measured on the contralateral arm by the cuff technique. Next, 
sulfaphenazole (Merck Biosciences AG, Läufelfingen, Switzerland; diluent saline 0.9 %) 
was infused (4 mg/min for 5 minutes) intra-arterially (brachial artery), followed by intra-
arterial saline infusion during arterial occlusion and determination of FMD after release 
of arterial occlusion. It has been reported previously that administration of a similar dose 
of sulfaphenazole resulted in local plasma levels, high  enough to effectively inhibit CYP 
2C acitivity10.  Next, N-monomethy-L-arginine (L-NMMA, Calbiochem, CN Biosciences, 
La Jolla, CA, USA; in saline 0.9 %) was infused intra-arterially (brachial artery) to inhibit 
the endothelial NO synthase (7 µmol/min for 5 minutes), FMD was determined after 
wrist arterial occlusion for 8 minutes. After again obtaining baseline levels, an intra-
arterial (brachial artery) co-infusion of sulfaphenazole and L-NMMA (doses as 
mentioned above, each 5 min) was performed and FMD was determined. Finally an 
intra-arterial (brachial artery) infusion of sodium-nitroprusside (SNP; Schwarz Pharma, 
Monheim, Germany; 9 µg/min for 5 minutes in saline 0.9 %) to assess endothelium-
independent vasodilatory capacity was performed.  
All measurements were performed in a quiet room with an ambient temperature 
between 22° and 24° C. Alcohol and caffeine were prohibited within 12 hours of the 
study.  
 
Immunhistochemistry 
Radial artery specimens were obtained from patients who underwent coronary artery 
bypass graft surgery (n=6). Freshly isolated radial artery specimens were washed in ice 
cold PBS and immediately embedded in tissue freezing medium (Jung) and stored at -
80°C. Frozen sections were fixed in phosphate-buffered formaldehyde solution (4%), 
permeabilized using Triton X-100 (0.2%) and blocked with bovine serum albumin 
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solution (3%) and horse serum (5%) in phosphate-buffered saline. CYP 2C was 
detected using a specific polyclonal CYP 2C antibody (kindly provided by Dr. E. 
Morgan, Atlanta, GA) and ß-actin using a monoclonal antibody (Sigma). Preparations 
were then washed and incubated with fluorescent secondary antibodies (Alexa), 
mounted and images were acquired by laser scanning microscopy (LSM 510 meta, Carl 
Zeiss, Jena, Germany). 
 
Statistics 
Data are expressed as the mean ± SEM and data were analyzed by ANOVA for 
repeated measures followed by Student Newman Keuls test.  A value of p < 0.05 was 
considered to be statistically significant.  
 
Results 
Arterial blood pressure and heart rate did not change during the study protocol. The 
intra-arterial infusion of sulfaphenazole was well tolerated, and no side effects were 
observed.  Radial arterial diameters are depicted in table 3 (healthy subjects) and table 
4 (heart failure patients). No changes of the baseline diameter were observed after 
infusion of sulfaphenazole or L-NMMA.  
Effect of sulfaphenazole on FMD 
FMD during infusion of saline was 11.5 + 0.87 %, FMD during infusion of 
sulfaphenazole was 7.4 + 0.95 %, p<0.01. Thus, FMD of the radial artery was 
significantly reduced during infusion of sulfaphenazole (figure 1). To determine whether 
an effect of sulfaphenazole was also apparent after inhibition of the NO synthase, FMD 
was determined during infusion of the NO synthase inhibitor L-NMMA (6.0 + 0.78 %) as 
well as during the co-infusion of both compounds (FMD 3.9 + 0.73 %). The co-infusion 
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resulted in a further significant inhibition of FMD as compared to L-NMMA alone in 
healthy subjects (figure 1). 
Effect of Sulfaphenazole on endothelium-independent vasodilation 
To determine whether the effect of sulfaphenazole is specific for endothelium-mediated 
vasodilation, we assessed the effect of sulfaphenazole on endothelium independent 
relaxation elicited to sodium nitroprusside (SNP). As shown in figure 2, sulfaphenazole 
had no effect on the SNP-induced, endothelium-independent vasodilation (FMD 19.6 + 
1.87 % vs 20.2 + 2.16 %, p= n.s).  
Effect of drugs infusions on reactive hyperemic blood flow 
Blood flow before and after release of the cuff was assessed to ascertain whether or not 
the stimulus, i.e. the increase in flow, was similar during the different drug infusions. 
Blood flow at rest was significantly reduced after sulfaphenazole infusion in healthy 
subjects (table 3), however, neither of the compounds had a significant effect on 
reactive hyperemic blood flow, suggesting that the stimulus for flow-dependent dilation 
was similar in all groups.  The results for radial artery blood flow are depicted in table 3 
for healthy subjects and in table 4 for heart failure patients. 
Effect of sulfaphenazole on FMD in patients with heart failure 
When compared with responses observed in healthy volunteers, flow-mediated dilation 
was attenuated in patients with heart failure. Sulfaphenazole significantly reduced FMD 
in patients with heart failure (p<0.01), an effect that was similar to the observations in 
healthy volunteers. The co-infusion of L-NMMA and sulfaphenazole caused an 
additional reduction in FMD compared to the infusion of L-NMMA alone. Sulfaphenazole 
had no effect on the endothelium-independent vasodilation elicited by SNP in patients 
with heart failure (data not shown). To analyse the effect of sulfaphenazole in severe 
heart failure patients,  subjects were divided in two groups. One group had a FMD lower 
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than the median (7.76%), the other group had a FMD greater than the median. 
However, there was still a significant inhibition of FMD after infusion of sulfaphenazole 
in patients with a FMD below the median value (FMD control 5.7 + 0.49 %, FMD after 
sulfaphenazole infusion 3.4 + 0.72 %, p < 0.05). 
 
Immunhistochemical detection of CYP 2C in radial arteries  
In immunhistochemical studies, the expression of CYP 2C protein was detected in 
endothelial cells and in some samples in cells infiltrating the medial layer of the radial 
artery (figure 4), the vessel segment which was investigated in vivo by our echotracking 
device. 
 
Discussion 
The results of the present study demonstrate that FMD in human conductance arteries 
is substantially reduced after inhibition of CYP 2C9 supporting the concept that a factor 
generated by this enzyme contributes to flow-mediated, endothelium-dependent 
vasodilation of peripheral conduit arteries in vivo. In patients with heart failure, the CYP-
dependent FMD appears to be preserved. Importantly, the expression of CYP 2C was 
detected by immunhistochemistry in radial artery samples obtained from patients 
undergoing coronary bypass surgery, the same vascular bed in which FMD-
measurements were performed in the in vivo studies. 
Recent studies by our group and others have shown that the dila tion of conduit arteries 
in response to reactive hyperemia is reduced by inhibitors of NO synthesis, suggesting 
an important role of NO in FMD1-3. However, several reports have indicated that FMD is 
a complex phenomenon involving the synthesis and release of more than one factor 
and that a substantial portion of the response may be independent of NO production2,3. 
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In both animals and humans, coronary FMD in response to prolonged hyperemia has 
previously been reported to be resistant to NO synthase inhibition.9,11  
Recently, Archer et al.6 demonstrated that human left internal mammary arteries 
express CYP 2C9, generate 11,12-EET and induce the hyperpolarization of vascular 
smooth muscle cells in response to stimulation. Indeed, based on the fact that NO- and 
prostacyclin-independent, or EDHF-mediated responses in the mammary arteries 
studied were sensitive to a CYP epoxygenase inhibitor, a CYP 2C-like EDHF synthase 
was suggested to account or approximately 40% of the net endothelium-dependent 
relaxation in vitro. This quantitative estimation of the contribution of EDHF to 
endothelium-dependent relaxation is consistent with our present in vivo observations in 
human conduit arteries, using increased flow as a stimulus. In agreement with the 
observations made by Archer et al.6, who found CYP 2C expression in left internal 
mammary arteries, we found that CYP 2C is expressed in a human radial artery. 
Although a sulfaphenazole-sensitive process was previously reported to contribute to 
the phenomenon of exercise-induced hyperaemia in skeletal muscle of healthy 
volunteers,12 three recent studies have reported that CYP 2C does not contribute to the 
agonist- induced vasorelaxation of human forearm resistance arteries.9,10,13 The 
reasons for these contrasting findings are not entirely clear but are most probably 
related to the differential expression of CYP 2C enzymes in different vascular beds.  
Indeed, CYP 2C is not homogenously expressed throughout the vasculature and even 
within the porcine coronary circulation there are marked differences.14 Thus, it is 
possible that the apparent lack of effect of sulfaphenazole reported in previous studies 
can be attributed to the fact that the vasodilations elicited by acetylcholine and 
bradykinin reflect an integrated response in CYP 2C-expressing as well as CYP 2C-
deficient vessels. It cannot be excluded, however, that FMD is a better activator of the 
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CYP expressed in endothelial cells than the agonists that are generally used to assess 
vasodilator function.  We have observed that CYP 2C is expressed in the human radial 
artery and sulfaphenazole attenuates the FMD of this artery, indicating that a CYP 2C 
enzyme contributes to the NO- and prostacyclin-independent (EDHF-mediated) 
responses in human conduit arteries, rather than in the forearm microcirculation. 
In the latter vascular bed however, i.e. in the forearm microcirculation, an increase in 
the activity of a CYP 2C enzyme has been associated with a markedly different effect 
and Fichtlscherer et al.9 reported that in patients with manifest coronary artery disease 
the inhibition of CYP 2C results in a marked improvement of the acetylcholine-
stimulated, endothelium-dependent and NO-mediated vasodilations. The latter effect 
was attributed to the inhibition of CYP 2C-derived reactive oxygen species which would 
be expected to react with NO and thus decrease its bioavailability.8,9  Similarly, in 
patients with hypertension there a pronounced effect of sulfaphenazole on the 
acetylcholine stimulated endothelium-dependent vasodilation has recently been 
observed.13 In the present study we have characterized for the first time the effect of 
sulfaphenazole on the endothelium-dependent vasodilation in patients with chronic 
heart failure in a conductance artery.  In patients with heart failure, sulfaphenazole had 
a similar effect on endothelium-dependent vasodilation as compared to healthy 
subjects, suggesting that the CYP2C response cannot compensate for impaired NO-
mediated vasodilation in patients with CHF.   
A number of different factors and/or mechanisms have been proposed to underlie the 
EDHF phenomenon and compensate for the loss of NO by acting as a back up system 
to maintain FMD (for review see 15). The literature relating to the identity of putative 
EDHFs is highly confusing, perhaps more so since - in addition to the release of 
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hyperpolarizing concentrations of K+ ions from endothelial cells or a CYP 2C-derived 
metabolite of arachidonic acid,15 -endothelium-derived H2O2 has also been proposed to 
act as an EDHF in human and murine arteries.16-19 Notably, Miura et al. have reported 
that an H2O2-like EDHF contributes more to FMD in patients with coronary artery 
disease (CAD) than in individuals without CAD.17 Since a CYP 2C epoxygenase is a 
functionally significant source of reactive oxygen species within the vascular wall 8 and 
H2O2 may act as an EDHF16 it is tempting to speculate that a CYP enzyme may underlie 
both responses.  
As NO-mediated responses are attenuated in heart failure and physiologically relevant 
concentrations of NO attenuate CYP activity in healthy vessels20,21, we expected the 
attenuated NO-dependent responses to be associated with an alleviation of the 
intrinsically inhibited EDHF response. However, rather than recording a more 
pronounced contribution of EDHF to FMD in patients with chronic heart failure we found 
that the inhibitory effects of sulfaphenazole on FMD were comparable in normal 
individuals and in patients with heart failure. At this point it is important to note that in 
previous studies have shown that NO-dependent FMD is impaired in patients with heart 
failure.1,2 However in the present investigation, the extent of blockade of FMD by L-
NMMA was somewhat reduced as compared to our earlier studies 1,2.  Our patients 
were treated with ACE-inhibitors, statins and aldosterone inhibitors which, in contrast to 
our previous observations1,2, have all been shown to improve endothelial function, at 
least partly, by reducing oxidative stress.22-24 Drug treatment may even increase the 
expression of CYP 2C as nifedipine25, cerivastatin and fluvastatin26 have all been 
reported to increase CYP 2C expression in endothelial cells and in isolated arteries in 
vitro. Thus it is possible that these compounds also indirectly affected responsiveness 
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to sulfaphenazole by interfering with the generation of reactive oxygen species and/or 
the generation and actions of the CYP-derived EDHF/EET´s. Effective treatment of 
heart failure patients is associated with a reduced oxidative stress and may indeed 
provide an explanation for the fact, that NO-mediated FMD was not impaired in the 
patient population studied. 
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Figure legends 
 
Figure 1: Change in radial artery diameter (%) during reactive hyperemia (flow-
dependent dilation) after wrist occlusion in healthy volunteers under control conditions 
(saline infusion) and after infusion of sulfaphenazole, L-NMMA and co-infusion of 
sulfaphenazole and L-NMMA) 
 
Figure 2: Change in radial artery diameter (%) during reactive hyperemia (flow-
dependent dilation) after wrist occlusion in patients with chronic heart failure under 
control conditions (saline infusion) and after infusion of sulfaphenazole, L-NMMA and 
co-infusion of sulfaphenazole and L-NMMA). 
 
Figure 3: Results of immunhistochemical studies of radial artery specimens (n=6) 
obtained from patients undergoing coronary bypass surgery. CYP2C is labeled red, β-
actin is labeled green and VE-cadherin is labeled blue. The arrows point to the 
endothelial cells stained for CYP 2C.  
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 Table 1: Baseline characteristics (healthy volunteers, n=12) 
___________________________________________________________________ 
Age       24.2 + 3.3 years 
 
Gender, male     9 (75) 
 
Hypertension     0 
 
Current Smoker     0 
 
Total cholesterol, mg/dl    158.8 + 10.7 
 
LDL-Cholesterol, mg/dl    103.3 + 9.8 
 
HDL-Cholesterol, mg/dl    54.4 + 2.4 
 
CRP, mg/l      3.3 + 0.8 
 
 
mean + SEM 
Figures in parentheses are percentages 
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Table 2: Baseline characteristics (CHF patients, n=12) 
___________________________________________________________________ 
Age     66.8 + 2.1 years 
 
Gender, male   11 (92) 
 
Ischemic cardiomyopathy  8 (75) 
 
Dilated cardiomyopathy  4 (25) 
 
NYHA functional class II  3 (25) 
 
NYHA functional class III  9 (75) 
 
Hypertension   8 (75) 
 
Current smoker   0 
 
NT-pro BNP, ng/l   2804 + 961 
 
CRP, mg/l    17 + 9 
 
Hemoglobin, g/dl   13.7 + 0.6 
 
Serum sodium, mmol/l  137 + 1.2 
 
Serum creatinine, µmol/l  104 + 12 
 
Total cholesterol, mg/dl  175 + 20 
 
LDL cholesterol, mg/dl  110 + 15 
 
HDL cholesterol, mg/dl  43 + 5 
 
Medical treatment 
 
ASA     9 (75) 
 
ACE-inhibitor/AT-blocker  12 (100) 
 
ß-blocker    11 (92) 
 
Diuretics    10 (83) 
 
Spironolactone   8 (67) 
 
Statin     8 (67) 
 
mean + SEM; Figures in parentheses are percentages 
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Table 3: Radial arterial diameters and radial artery blood flow at baseline and during 
reactive hyperemia in healthy vo lunteers: Effect of sulfaphenazole, L-NMMA and co-
infusion. 
_________________________________________________________________ 
 
Arterial diameter, mm Baseline  Reactive hyperemia  Absolute change  
 
Control   2.692 + 0.10  3.010 + 0.12  0.317 + 0.03 
 
Sulfaphenazole infusion 2.692 + 0.09  2.883 + 0.11* 0.191 + 0.03* 
 
L-NMMA infusion  2.707 + 0.08  2.872 + 0.09* 0.166 + 0.02* 
 
Co-infusion   2.725 + 0.08  2.831 + 0.09* 0.106 + 0.02* 
 
 
Radial artery blood flow, ml/min Baseline   Reactive hyperemia 
    
 
Control    19.79 + 3.31   43.66 + 5.86  
  
Sulfaphenazole infusion  15.06 + 3.40 *  44.57 + 5.33  
 
L-NMMA infusion   18.78 + 2.36   44.04 + 6.05  
 
Co-infusion    15.16 + 3.78 *  45.18 + 5.46  
 
 
mean + SEM; * p<0.05 vs. control infusion 
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Table 4: Radial arterial diameters and radial artery blood flow at baseline and during 
reactive hyperemia in heart failure patients: Effect of sulfaphenazole, L-NMMA and co-
infusion. 
_________________________________________________________________ 
 
Arterial diameter, mm Baseline  Reactive hyperemia  Absolute change  
 
Control   3.198 + 0.13  3.460 + 0.15  0.262 + 0.04 
 
Sulfaphenazole infusion 3.245 + 0.13  3.398 + 0.13* 0.153 + 0.02* 
 
L-NMMA infusion  3.233 + 0.14  3.359 + 0.14* 0.126 + 0.02* 
 
Co-infusion   3.265 + 0.13  3.358 + 0.13* 0.093 + 0.01* 
 
 
Radial artery blood flow, ml/min Baseline   Reactive hyperemia 
    
Control    29.97 + 7.55   60.15 + 10.09  
 
Sulfaphenazole infusion  27.02 + 7.23   51.02 + 7.33  
 
L-NMMA infusion   22.79 + 4.3   49.82 + 7.37  
 
Co-infusion    24.84 + 3.73   50.71 + 5.46  
 
 
mean + SEM; * p<0.05 vs. control infusion 
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Figure 1: Endothelium-mediated, flow-dependent vasodilation of 
peripheral conduit arteries in healthy volunteers (n=12).
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Figure 2:      Endothelium-mediated, flow-dependent vasodilation of 
peripheral conduit arteries in patients with heart failure (n=12).
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Figure 3
Cytochrome P450 2C9 is involved in flow-dependent vasodilation of peripheral conduit arteries in 
healthy subjects and in patients with chronic heart failure. 
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